Alumis Inc. (ALMS): Investor Outlook Reveals 35% Upside Potential In Biotech Sector
Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company, is showing significant upside potential in the biotech sector, with analysts projecting a 35% increase from its current share price of $27.51 to an average target of $37.25. The company specializes in treating autoimmune disorders and has a market capitalization of $3.43 billion. Despite being in an aggressive investment phase with negative free cash flow, Alumis is backed by strong analyst support and a promising clinical pipeline, including therapies for psoriasis, lupus, and neuroinflammatory diseases.
Alumis Inc stock hits all-time high at 28.34 USD
Alumis Inc. stock has reached an all-time high of $28.34, reflecting a significant 430.21% increase over the past year. Despite its impressive performance and positive analyst price targets ranging from $32 to $50, InvestingPro data suggests the stock might be overvalued and analysts do not expect profitability for the current fiscal year. The company recently closed a successful public offering, raising $345.1 million, and received positive analyst coverage following promising Phase III trial results for its lead asset, envudeucitinib.
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS
Credit Industriel ET Commercial reduced its stake in Alumis Inc. by 36.2% in Q3, selling 140,000 shares, now owning 247,002 shares valued at $986,000. Meanwhile, major insiders Foresite Capital Management VI and Foresite Labs each purchased 411,764 shares on January 8th at $17.00 per share. Despite Alumis missing recent EPS and revenue estimates, analysts maintain a "Moderate Buy" consensus rating with a target price of $37.50.
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit
Alumis presented strong Phase III psoriasis data for envudeucitinib, showing significant lesion reduction and rapid onset with a favorable safety profile. The company plans an NDA filing in the second half of the year, contingent on further durability data, and anticipates near-term catalysts including Phase IIb lupus results and a new MS study. With $630 million in cash, Alumis is funded into late 2027 and is exploring strategic partnerships to optimize its TYK2 inhibitor franchise.
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook
BML Capital Management has sold its entire stake in Alumis (ALMS), coinciding with Alumis filing a new shelf registration and preparing for investor conferences. This move places a new focus on the biotech company's market perception and future capital plans. Investors are advised to monitor the execution of the shelf registration and the company's communications at upcoming conferences for insights into its direction and pipeline.
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook
BML Capital Management has completely divested its stake in Alumis (NasdaqGS:ALMS), a move coinciding with Alumis's new shelf registration filing and upcoming appearances at investor conferences. This shift draws market attention to reactions from other investors as Alumis prepares for increased market engagement and potential capital-raising activities. The company's stock currently trades below analyst targets, but key risks include high volatility and unprofitability.
Alumis to Participate in Upcoming February Investor Conferences
Alumis Inc. (Nasdaq: ALMS), a biopharma company, announced its participation in two investor conferences in February 2026. The company will have a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 and a presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Alumis focuses on developing targeted therapies for immune-mediated diseases using a proprietary data analytics platform.
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Alumis Inc. (NASDAQ:ALMS) has received a "Moderate Buy" consensus rating from eleven brokerages, with ten recommending "buy" and one "sell." The average 12-month price target is set at $37.50, following recent target increases from several major brokers. Insider buying activity has been significant, with Foresite Labs and director James B. Tananbaum acquiring over 411,000 shares each at $17.00, increasing their collective insider ownership to 40.7%.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
BML Capital Management sold its entire 1,210,415-share stake in Alumis (NASDAQ:ALMS) for an estimated $4.83 million before Alumis' stock surged significantly after an upsized public offering. Despite Alumis shares rallying 255.1% over the past year, the fund's decision, made before the January offering, was based on risk management for early-stage biotech. The market's positive reaction to the offering changed the narrative, causing the stock to reprice rapidly.
Alumis (NASDAQ:ALMS) Stock Price Up 9.8% - What's Next?
Alumis Inc. (NASDAQ:ALMS) saw its stock price increase by 9.8% on Monday, trading up to $26.90 with thinner than usual trading volume. Analysts maintain a "Moderate Buy" consensus with an average target price of $37.50, and recent insider buying activity, including significant purchases by major shareholder Foresite Capital, indicates strong internal confidence. The company aims to develop targeted therapies in immunology, focusing on two Tyrosine Kinase 2 (TYK2) inhibitors.
Alumis Inc stock (ALMS) jumps again on Nasdaq — here’s what’s driving the move and what comes next
Alumis Inc. stock (ALMS) surged by 6.7% to $26.15 on Nasdaq, continuing its recent volatility, likely driven by a strengthening biotech market and increased risk appetite among investors, rather than new company news. The company is in clinical development, focusing on oral TYK2 inhibitors for psoriasis, with strong late-stage trial results for envudeucitinib announced in January, which it aims to file for U.S. approval in the second half of 2026. Investors are now awaiting Alumis's upcoming financial update, expected around March 18, for details on cash runway and filing timelines.
Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials
Chardan has highlighted Alumis's (ALMS) potential following positive results from its phase 3 psoriasis trials for envudeucitinib. The drug successfully met all primary and secondary endpoints, demonstrating strong efficacy and safety. This development positions Alumis favorably in the dermatology market and validates its TYK2 inhibitor platform.
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January
Alumis Inc. (NASDAQ:ALMS) experienced a significant surge in short interest in January, increasing by 93.1% to 8,672,088 shares, representing 14.0% of its shares sold short. Despite this, analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $37.50. Additionally, company insiders, including Foresite Capital and Director Srinivas Akkaraju, made substantial purchases of ALMS stock at $17 per share.
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials
Chardan initiated coverage on Alumis (ALMS) with a Buy rating and a $37 price target, citing the significant potential of its autoimmune pipeline. This follows envudeucitinib successfully meeting all primary and secondary endpoints in two Phase III trials for moderate-to-severe plaque psoriasis, prompting other firms like H.C. Wainwright and Morgan Stanley to raise their price targets for the company. Alumis Inc. (NASDAQ:ALMS) is a clinical-stage biopharmaceutical company developing medicines for autoimmune disorders.
10 New Stocks on the Rise
This article highlights Alumis Inc. (NASDAQ: ALMS) as one of the new stocks on the rise. Several financial firms, including Chardan, H.C. Wainwright, and Morgan Stanley, have initiated or raised price targets and ratings for Alumis due to positive Phase III trial results for its drug envudeucitinib, which treats moderate-to-severe plaque psoriasis. The company, a clinical-stage biopharmaceutical firm focusing on autoimmune disorders, has seen a 1-month performance of 138.92% and is held by 26 hedge funds.
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials
Chardan has initiated coverage of Alumis (ALMS) with a Buy rating and a $37 price target, citing the strong potential of its autoimmune pipeline. This follows successful Phase 3 trials for Alumis's TYK2 inhibitor, envudeucitinib, in moderate-to-severe plaque psoriasis, which met all primary and secondary endpoints. Other firms like H.C. Wainwright and Morgan Stanley have also increased their price targets and ratings for Alumis based on these positive results, anticipating reduced regulatory risk and higher revenue potential for the company.
Alumis stock hits all-time high at 27.28 USD
Alumis Inc. (ALMS) stock reached an all-time high of $27.45, reflecting strong investor confidence and a 293.34% one-year return. The biotechnology company, with a market capitalization of $3.24 billion, recently raised $345.1 million through a public offering and saw increased price targets from analysts following positive Phase III trial results for its oral TYK2 inhibitor, Envudeucitinib.
Alumis (NASDAQ:ALMS) Trading Up 6.4% - Should You Buy?
Alumis (NASDAQ:ALMS) saw its shares jump 6.4% to $26.09, despite weak trading volume. Analyst sentiment is generally positive with a "Moderate Buy" rating and an average price target of $37.50, and insiders have been actively buying shares. However, the company recently missed its quarterly EPS and revenue estimates, and alternative stock options are suggested for investors.
Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Chardan Capital
Chardan Capital has initiated coverage on Alumis (NASDAQ:ALMS) with a "buy" rating and a $37 price target, reflecting a potential 38.7% upside. This follows other recent upgrades, contributing to a consensus "Moderate Buy" rating and a $37.50 target. Despite the positive analyst sentiment and recent insider purchases totaling $49.35 million, Alumis recently missed quarterly EPS and revenue estimates, operating with a negative P/E ratio and showing significant stock volatility.
Alumis Inc. (ALMS) Stock Analysis: Exploring A 39% Upside In The Biotech Arena
Alumis Inc. (ALMS) is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune disorders, showing a potential upside of nearly 40% according to analysts. Despite operating without revenue and having negative EPS, its strong pipeline—including TYK2 inhibitors ESK-001 and A-005—and positive technical indicators suggest bullish momentum. The company represents a high-risk, high-reward opportunity, with its long-term growth tied to successful drug approvals.
Chardan Capital initiates coverage on Alumis stock with Buy rating By Investing.com
Chardan Capital Markets has initiated coverage on Alumis Inc. (NASDAQ:ALMS) with a Buy rating and a price target of $37.00. The coverage highlights Alumis's lead asset, envudeucitinib, an oral TYK2 inhibitor, which met all primary and secondary endpoints in two Phase III trials for moderate-to-severe plaque psoriasis. The company plans to submit a New Drug Application in the second half of 2026 for this indication.
Chardan Capital initiates coverage on Alumis stock with Buy rating
Chardan Capital Markets has initiated coverage on Alumis Inc. (NASDAQ:ALMS) with a Buy rating and a $37.00 price target, highlighting the potential of its lead asset, envudeucitinib, for plaque psoriasis. The drug showed strong Phase III trial results, achieving primary and secondary endpoints. This follows a successful $345.1 million public offering and positive analyst updates from Guggenheim and Oppenheimer, who also raised their price targets for Alumis.
Alumis (NASDAQ:ALMS) Hits New 12-Month High - What's Next?
Alumis Inc. (NASDAQ:ALMS) recently hit a new 52-week high of $25.30, trading up about 9.2%. This surge comes despite a recent EPS miss, but is supported by bullish analyst ratings with a consensus "Moderate Buy" and a $37.67 price target, as well as significant insider buying from major shareholders. Insiders now own approximately 40.7% of the stock, indicating strong internal confidence.
Alumis stock reaches all-time high at 25.25 USD By Investing.com
Alumis Inc. stock has hit an all-time high of $25.25 USD, surpassing its previous 52-week high, driven by strong investor confidence and strategic advancements in the biotechnology sector. The company recently completed an upsized public offering, raising approximately $345.1 million, and has received raised price targets from Guggenheim and Oppenheimer following positive Phase III trial results for its psoriasis treatment, envudeucitinib. This significant surge reflects a 234.68% increase in stock value over the past year.
Alumis stock reaches all-time high at 25.25 USD
Alumis Inc. stock has hit an all-time high of $25.25 USD, surpassing its previous 52-week high of $25.19, reflecting a 234.68% increase over the past year. This surge is attributed to growing investor confidence, strategic advancements, and recent positive developments, including a successful upsized public offering of $345.1 million and increased price targets from Guggenheim and Oppenheimer following positive Phase III trial results for its psoriasis treatment.
Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise
Alumis (ALMS) shares surged by 22.0% following positive Phase 3 clinical trial results for its psoriasis drug, envudeucitinib, and a successful $300 million equity raise. This news, coupled with insider share purchases and plans for FDA approval, positions envudeucitinib as a significant asset in immunology, addressing previous funding concerns. The company's future catalysts include an NDA filing in late 2026 and upcoming SLE data.
Alumis (ALMS) Is Up 35.8% After Psoriasis Data And $300M Raise Has The Bull Case Changed?
Alumis (ALMS) saw its stock rise by 35.8% following positive Phase 3 results for its oral TYK2 inhibitor envudeucitinib in psoriasis and a subsequent $300 million stock offering. The company's investment narrative now hinges on the success of envudeucitinib, with upcoming milestones including an NDA submission and Phase 2b lupus trial readouts. Investors should consider the potential for further dilution and the concentration risk given the reliance on a single drug candidate, as indicated by varied fair value estimates from the Simply Wall St community.
HC Wainwright & Co. Hikes Alumis Inc. (ALMS)’s Price Target To $40 From $20, Reiterates Buy Rating
HC Wainwright & Co. has raised its price target for Alumis Inc. (ALMS) to $40 from $20, while reiterating a Buy rating. This adjustment follows positive Phase 3 trial results for envudeucitinib in treating plaque psoriasis, which achieved primary and secondary endpoints and demonstrated safety and efficacy. The firm anticipates FDA approval for the drug, potentially leading to significant revenue growth for Alumis.
HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating
HC Wainwright & Co. has significantly increased its price target for Alumis Inc. (ALMS) from $20 to $40, maintaining a Buy rating. This adjustment follows promising Phase 3 trial results for envudeucitinib, Alumis's drug for moderate to severe plaque psoriasis, which met primary and secondary endpoints and showed good tolerability. Analysts foresee a strong potential for FDA approval and a major revenue boost for the company.
HC Wainwright & Co. Hikes Alumis Inc. (ALMS)’s Price Target To $40 From $20, Reiterates Buy Rating
HC Wainwright & Co. raised its price target for Alumis Inc. (ALMS) to $40 from $20 and reiterated a Buy rating following positive Phase 3 trial results for envudeucitinib in treating plaque psoriasis. The trials met primary and secondary endpoints, demonstrating efficacy, safety, and improved quality of life for patients. Alumis plans to file for FDA approval in late 2026, with analysts anticipating significant revenue growth and a consensus Strong Buy rating for the stock.
Alumis (ALMS) Is Up 35.8% After Psoriasis Data And $300M Raise Has The Bull Case Changed?
Alumis Inc. (ALMS) saw a 35.8% stock increase after reporting positive Phase 3 results for its oral TYK2 inhibitor, envudeucitinib, in psoriasis and completing a $300.05 million stock offering. The company is now focused on NDA submission and awaiting Phase 2b lupus data, with investors weighing the potential of envudeucitinib against dilution and concentration risks. Simply Wall St's analysis suggests the current share price might be inflated compared to its estimated value.
Alumis (NASDAQ:ALMS) Stock Price Up 6.6% Following Insider Buying Activity
Alumis (NASDAQ:ALMS) saw its stock price rise by 6.6% after significant insider buying activity, with Director Srinivas Akkaraju, Foresite Labs, and Director James B. Tananbaum collectively purchasing millions of dollars worth of shares. This insider confidence, alongside positive plaque-psoriasis trial results and raised analyst price targets, contributed to the stock's uplift. Despite the positive sentiment, the company remains unprofitable and recently missed its EPS and revenue estimates, posing a risk if future clinical or execution results fall short.
Alumis' Meteoric Rise To $20 From $5 In Just 60 Days On Plaque Psoriasis Trial Results
Alumis Inc. (ALMS) has seen a significant stock increase from $5 to over $20 in 60 days following positive Phase 3 trial results for its lead product, Envudeucitinib, in plaque psoriasis. Envudeucitinib is an oral TYK2 inhibitor, a drug class with limited competition, and demonstrated superior skin clearance in trials with plans for an FDA New Drug Application submission this year. The company's stock surge highlights investor confidence in the drug's potential in the immune-mediated disease market.
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Follow On Equity Offering
Alumis Inc. (ALMS) has garnered attention following positive Phase 3 clinical trial results for its psoriasis drug, envudeucitinib, and a subsequent US$300.05 million equity offering. The company's share price has seen significant recent gains, indicating strong investor interest. While Alumis's Price-to-Book ratio of 7.2x is higher than the broader industry average, it trades at a discount compared to a closer peer group, suggesting a nuanced valuation despite ongoing losses.
Alumis (ALMS) Price Target Increased by 79.14% to 36.28
Alumis (ALMS) has seen its average one-year price target increase by 79.14% to $36.28 per share, up from $20.25 on December 18, 2025. This new target represents a 63.99% increase from its last reported closing price of $22.12. Despite this, the fund sentiment shows a slight institutional share decrease and a bearish put/call ratio of 1.12.
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Follow On Equity Offering
Alumis (ALMS) is under valuation review following positive Phase 3 data for its psoriasis treatment, envudeucitinib, and a successful US$300.05 million equity offering. The company has seen significant stock price momentum, trading at US$22.11, below the average analyst target of US$37.29. Its Price-to-Book ratio of 7.2x indicates investors are valuing its pipeline and future revenue potential despite current unprofitability, positioning it richly compared to the broader US Pharmaceuticals industry but at a discount to closer peers.
Diretor da Alumis compra ações no valor de US$ 9,9 milhões
O diretor Srinivas Akkaraju da Alumis INC. adquiriu 588.235 ações ordinárias no valor de US$ 9,9 milhões a US$ 17,0 cada. Atualmente, as ações estão sendo negociadas com um prêmio de 30% e subiram 36% na última semana. A empresa também realizou uma oferta pública ampliada de US$ 345,1 milhões e recebeu feedback positivo de analistas após ensaios bem-sucedidos da Fase III para seu medicamento Envudeucitinib, levando a aumentos nos preços-alvo por Guggenheim e Oppenheimer.
Akkaraju of Alumis buys shares worth $9.9 million
Director Srinivas Akkaraju of Alumis INC. acquired 588,235 shares of the company's common stock for $9.9 million on January 9, 2026, at $17.0 per share. This purchase appears well-timed as the stock has since surged by 36% in a week, now trading at a 30% premium to his purchase price and near its 52-week high. Analysts maintain a "Strong Buy" consensus for ALMS, with price targets ranging from $32 to $50.
Alumis Inc stock hits all-time high at 22.33 USD
Alumis Inc. stock has reached an all-time high of $22.33, marking a significant milestone for the $2.39 billion biotech company with a 1-year return of 192.92%. This surge follows a successful upsized public offering and positive analyst ratings from Guggenheim and Oppenheimer, who raised their price targets based on favorable results from drug trials.
Latham & Watkins Advises on Alumis’ Upsized US$345 Million Public Offering of Common Stock
Latham & Watkins LLP advised the underwriters in Alumis Inc.'s upsized underwritten public offering, which saw the clinical-stage biopharmaceutical company raise approximately US$345 million. Alumis sold shares of its common stock at US$17 per share. The Latham & Watkins team included specialists in capital markets, healthcare, FDA matters, executive compensation, tax, intellectual property, and data privacy.
Alumis raises $345.1 million in upsized public offering
Alumis Inc. successfully closed an upsized public offering, raising approximately $345.1 million by selling 20,297,500 shares at $17.00 each, including the full exercise of underwriters' option. The clinical-stage biopharmaceutical company, now valued at about $1.9 billion, is developing treatments for immune-mediated diseases. The offering follows recent positive Phase III trial results for its TYK2 inhibitor, Envudeucitinib, which led to increased price targets from several analysts.
Alumis Insider Bought Shares Worth $6,999,988, According to a Recent SEC Filing
An insider at Alumis Inc. (ALMS) recently purchased shares valued at $6,999,988, as reported in a new SEC filing. This transaction follows other significant insider purchases in recent months. Alumis is a clinical-stage biopharmaceutical company focused on developing TYK2 inhibitors for immune-mediated diseases.
Alumis (ALMS) director Tananbaum buys shares worth $6.99m
Alumis Inc. director James B. Tananbaum recently purchased 411,764 shares of the company's common stock for nearly $7 million, at a price of $17.00 per share. This insider buying follows Alumis's impressive 500% returns over the last six months, despite not being profitable, and comes after a successful upsized public offering and positive Phase III trial results for its psoriasis treatment. Analysts from Guggenheim and Oppenheimer have raised their price targets for ALMS, reflecting significant investor confidence.
Foresite Labs buys Alumis (ALMS) shares worth $7 million
Foresite Labs and its affiliate purchased a total of 411,764 shares of Alumis Inc. (ALMS) for approximately $7 million on January 8, 2026. The shares were bought at $17.00 each, which is below the current trading price. This insider buying follows Alumis's strong market performance and successful public offering, alongside positive analyst ratings due to promising clinical trial results for its drug Envudeucitinib.
Foresite Capital buys Alumis (ALMS) shares worth $7m
Foresite Capital entities have purchased Alumis Inc. (ALMS) shares worth approximately $7 million, with individual shares bought at $17.00. Since the transaction, ALMS stock has risen by 24% to $21.09. Alumis recently completed an upsized public offering, raising about $345.1 million, and analysts have set price targets between $32 and $50 after positive trial results for its drug Envudeucitinib.
Foresite Labs compra ações da Alumis (ALMS) no valor de US$ 7 milhões
Foresite Labs, LLC e Foresite Labs Affiliates 2021, LLC, proprietárias de dez por cento da Alumis Inc (ALMS), compraram um total de 411.764 ações ordinárias da Alumis em 08.01.2026, totalizando quase US$ 7 milhões. As compras foram feitas a US$ 17,00 por ação, valor abaixo do preço atual de negociação. Esta transação segue uma oferta pública ampliada bem-sucedida que levantou US$ 345,1 milhões e análises de mercado otimistas, com analistas elevando os preços-alvo da ação.
Foresite Capital compra ações da Alumis (ALMS) no valor de US$ 7 milhões
Foresite Capital entities have purchased Alumis Inc. (ALMS) shares worth approximately US$ 7 million on January 8, 2026, at an acquisition price of US$ 17.00 per share. Following this transaction, ALMS shares have increased by 24% to US$ 21.09, and analysts have set future price targets between US$ 32 and US$ 50. The company recently completed an expanded public offering, raising US$ 345.1 million, and received positive analyst sentiment driven by strong results from its Envudeucitinib trials.
Alumis’ Phase III TYK2 data intensify psoriasis efficacy contest
Alumis reported positive top-line Phase III data for its TYK2 inhibitor, envudeucitinib, in plaque psoriasis, positioning it as a potential best-in-class oral therapy. The company plans a $175 million follow-on financing and aims to submit an NDA in the second half of 2026. Envudeucitinib met co-primary and secondary endpoints in two large-scale clinical trials.
Alumis Stock Skyrockets Amid Significant Drug Trial Success
Alumis Inc.'s stock surged over 133% following promising phase 3 clinical trial results for its oral drug, envudeucitinib, in treating plaque psoriasis. Despite the company's significant financial distress, including negative profitability metrics and operating losses, the breakthrough trial success has generated strong investor confidence, potentially positioning Alumis favorably within the Healthcare and Biotechnology sectors. The market's positive reaction highlights the potential for future revenue generation and corporate transformation, though sustained success depends on effective commercialization and ongoing regulatory navigation.
Alumis Stock Soars After Phase 3 Trial Success
Alumis Inc. (ALMS) stock surged by 8.64% after positive Phase 3 trial results for its investigational drug envudeucitinib. Despite ongoing financial challenges, including a significant pretax profit margin loss and negative cash flow, investor confidence has increased due to the drug's potential for treating plaque psoriasis and regulatory advancement. The company is at a critical point, and effective commercialization strategies will be essential for sustained growth and profitability.
